In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...

Pharmaceutical Executive: How can prohibitive costs for treatments be addressed? Lisa Bollinger: These are oftentimes very ...

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, who has worked in the obesity space since the ...

Price transparency remains limited due to heterogeneous baselines, missing “before” metrics, and variable sourcing models, ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...

Pharmaceutical Executive spoke with Lisa Bollinger, chief medical officer at Polaryx. The clinical-stage biotech focuses on ...

We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...

While Eli Lilly continues to ride an historic stretch of company growth and performance in the annals of Big Pharma, the now ...

Most terminated trials stop for enrollment and funding failures, not negative efficacy or safety, making data-collection cost ...